CASRAI Dictionary

Tag: biological material transfer agreement

  • Types of Material Transfer Agreement Guide: One-Way, Two-Way and Commercial-Use MTAs

    Types of material transfer agreement fall into two overlapping categories: direction of transfer (one-way versus two-way) and nature of the parties (academic/non-profit versus commercial-use). Choosing the wrong category adds weeks of unnecessary negotiation to a simple exchange, or leaves an institution exposed on intellectual property and liability in a complex one. A material transfer agreement (MTA) is a contract that governs the transfer of tangible research materials — cell lines, plasmids, reagents, antibodies, animal models, or genetic constructs — between a provider and a recipient, setting terms for permitted use, publication, and downstream rights.

    What is a material transfer agreement, and why does type matter?

    A material transfer agreement is the legal instrument accompanying the physical movement of a research material between organisations. It records who owns the original material, what the recipient may do with it, who owns derivatives the recipient creates, and what happens if the material leads to a publication or invention.

    Institutions do not use one template for every transfer. The right MTA type depends on two independent variables: direction of the exchange, and the nature of the parties — non-profit or commercial. Mismatching the template to either variable is a common cause of avoidable negotiation delay.

    One-way vs two-way MTAs: what is the difference?

    A one-way MTA covers a single direction of transfer: one provider sends material to one recipient, who accepts the provider’s terms. Most institutional MTAs are one-way and are further split into two sub-types depending on which side of the transaction the institution sits on.

    • Incoming MTA — the institution is the recipient. The priority is understanding and accepting the provider’s restrictions: permitted research use, any prohibition on commercial use, and publication or embargo terms.
    • Outgoing MTA — the institution is the provider. The priority shifts to protecting the institution’s own intellectual property, limiting liability for the material’s performance, and controlling further distribution by the recipient.

    A two-way (or reciprocal) MTA is used when both parties send materials to each other, typically in an active collaboration where each lab holds a resource the other needs. Rather than negotiate two separate one-way agreements, the parties combine both transfers into a single reciprocal agreement with symmetric obligations. This is administratively efficient but requires both sides to specify their respective materials and restrictions with equal precision — asymmetric two-way MTAs are a frequent source of later disputes over derivative rights.

    MTA type Direction Typical parties Primary administrative focus
    Incoming (one-way) Provider → institution Academic-to-academic or vendor-to-academic Compliance with provider’s use and publication restrictions
    Outgoing (one-way) Institution → external recipient Academic-to-academic or academic-to-industry IP retention, liability limitation, distribution control
    Two-way / reciprocal Bidirectional Collaborating academic labs Symmetric terms for both transferred materials
    Academic/non-profit Either direction Non-profit-to-non-profit Non-commercial research use only; minimal negotiation
    Commercial-use Either direction At least one for-profit party IP ownership, licensing options, publication delay, indemnification

    Academic/non-profit vs commercial-use MTAs: how do the terms differ?

    The second axis of classification is the nature of the parties, and it changes negotiation complexity more than direction does. A biological material transfer agreement between two non-profit universities is usually a light-touch document; the same transfer involving a commercial partner routinely takes months longer to close.

    Academic and non-profit MTAs exist to facilitate open scientific exchange. The US National Institutes of Health (NIH) has stated that unique research resources arising from NIH-funded work should be shared on terms no more restrictive than its own model agreements, because repeated case-by-case negotiation between non-profits delays the point at which a research tool reaches the laboratory bench. These agreements typically restrict use to non-commercial research, require no royalty, and rarely need individual negotiation once a standard template is adopted.

    Commercial-use MTAs — where a for-profit company is provider, recipient, or both — carry additional, negotiated terms that a non-profit template does not anticipate:

    • Intellectual property rights over inventions made using the transferred material, including whether the provider retains an option to license.
    • Publication rights, including any pre-publication review period the commercial party can invoke to protect confidential information.
    • Scope of permitted use, distinguishing internal research from development toward a commercial product, which may trigger the need for a separate licence agreement.
    • Indemnification and liability allocation, which non-profit-to-non-profit templates typically waive or cap at a nominal level.

    A material transfer agreement policy should specify, in advance, which of these terms are non-negotiable defaults and which require case-by-case legal review — allowing routine academic MTAs to clear in days, reserving negotiation capacity for the commercial-use cases where it is genuinely needed.

    Which standard templates exist, and how do you choose the right one?

    Four template families cover the great majority of transfers, and matching a transfer to the correct family is the fastest route to a signed agreement.

    • NIH Simple Letter Agreement (SLA), published in 1995 by the NIH, is a one-page model for low-risk, non-commercial transfers of routine research materials between non-profit institutions.
    • Uniform Biological Material Transfer Agreement (UBMTA), also introduced in 1995, is the master agreement signed once by an institution; individual transfers under it use a short “Implementing Letter” rather than a fresh negotiation, and it is the standard route for a two-way material transfer agreement between two UBMTA-signatory non-profits.
    • AUTM Model MTAs extend the UBMTA framework to materials — and non-US institutions — outside the UBMTA’s original definition of biological material; a 2011 AUTM member survey found low adoption of standard templates was itself a major cause of unnecessary delay, which the toolkit’s decision tree was built to address.
    • FAO Standard Material Transfer Agreement (SMTA), adopted by the Governing Body of the International Treaty on Plant Genetic Resources for Food and Agriculture in 2006, is a distinct global instrument governing plant genetic resources held in the Treaty’s Multilateral System, with mandatory benefit-sharing terms that have no equivalent in the UBMTA or NIH templates.

    To choose: start by identifying direction (one-way or two-way) and party type (non-profit or commercial). If both parties are non-profit and the material is biological, default to the UBMTA or SLA. If a commercial party is involved, route the transfer to legal review rather than a standard template. If the material is a plant genetic resource in the Multilateral System, the FAO SMTA applies regardless of the parties’ institutional type — a distinction general MTA guidance frequently omits.

    Frequently asked questions

    What is a material transfer agreement?

    A material transfer agreement is a contract governing the transfer of tangible research materials — such as cell lines, plasmids, reagents, or animal models — between a provider and a recipient. It sets terms for permitted use, ownership of derivatives, publication rights, and liability, and is negotiated before the physical material is shipped.

    What is the difference between an MTA and an NDA?

    An NDA (non-disclosure agreement) protects confidential information exchanged between parties, while an MTA governs the physical transfer and permitted use of a tangible material. The two are often signed together — an NDA may protect data about the material, while the MTA governs the material itself — but neither substitutes for the other.

    What is the standard material transfer agreement?

    The Standard Material Transfer Agreement (SMTA) is the FAO instrument used specifically for plant genetic resources held under the International Treaty on Plant Genetic Resources for Food and Agriculture’s Multilateral System. It is distinct from the UBMTA used for general biological materials and includes mandatory benefit-sharing obligations tied to the Treaty.

    Implications and outlook for research administrators

    Institutions that map every incoming request against this taxonomy before drafting — direction first, party type second, then template — process the majority of routine biological material transfer agreement requests without individual legal review. That triage is what standard templates like the UBMTA and NIH SLA were designed to enable, and what a written material transfer agreement policy should formalise as institutional default practice.

    The remaining minority — commercial-use transfers, cross-border plant genetic material, and asymmetric two-way exchanges — is where administrative time should concentrate, since these are the categories where the wrong template creates the greatest downstream IP and compliance risk. As collaborations increasingly span academic, industry, and international-treaty jurisdictions at once, classifying a transfer correctly at intake, rather than after a dispute arises, remains the most effective control a research administration office can apply.

  • Data Transfer Agreement vs MTA and CTA Explained

    A data transfer agreement (DTA) is the legal instrument that makes a specific movement of clinical trial data — to a third-party analyst, a data repository or a partner institution — lawful, bounded and auditable. It is not the same instrument as a material transfer agreement (MTA), which covers physical specimens, or a clinical trial agreement (CTA), which governs the whole trial relationship between sponsor and site. Research administrators who conflate the three risk leaving a data movement with no defined retention period, no cross-border transfer mechanism and no liability clause.

    A data transfer agreement is a standalone contract, separate from the CTA and the MTA, that fixes the permitted use, security safeguards, retention limits and legal transfer mechanism for a defined dataset moving from a data controller to a recipient. This article sets out what a clinical trial DTA covers that the other two instruments do not, and what clauses a compliant version must contain.

    What is a data transfer agreement in a clinical trial?

    A data transfer agreement is triggered whenever clinical trial data — identifiable, coded or fully anonymised — moves to a party not already bound by the trial’s main contracts: a central statistics unit, an academic secondary-use researcher, a data repository, or a partner sponsor in a licensing deal. The CTA the site signed with the original sponsor does not automatically extend data-handling obligations to that new recipient; the DTA is what does.

    Unlike a CTA, a DTA is narrow by design. It does not govern how the trial is run, who is paid what, or how adverse events are reported. It governs one thing only: the terms under which a defined dataset can be received, used, stored and eventually destroyed or returned.

    DTA vs MTA: data versus physical materials

    The distinction between a DTA and an MTA is the distinction between data and matter. A material transfer agreement governs blood, tissue, biopsies, cell lines or investigational compounds moving between institutions — tangible items that can be depleted, contaminated or physically lost. A DTA governs the dataset, not the specimen it may have been derived from.

    The two frequently travel together. A central laboratory sending biopsy slides to a specialist pathology reader needs an MTA for the slides and, if genomic or clinical annotation data accompanies them, a separate DTA for that dataset. Trying to cover data terms inside an MTA’s materials clauses is one of the most common gaps flagged in institutional research-contracting reviews.

    Instrument What moves Core legal basis Typical parties What it governs
    Data Transfer Agreement (DTA) Data — identifiable, coded or anonymised UK GDPR/EU GDPR Chapter V transfer mechanisms; HIPAA Data Use Agreement (US) Data controller/holder and a data recipient outside the original trial team Permitted use, retention, security, cross-border transfer mechanism
    Material Transfer Agreement (MTA) Physical specimens or compounds Institutional IP and biobanking policy Material provider and recipient institution or laboratory Ownership, permitted use, derivatives, liability
    Clinical Trial Agreement (CTA) The whole trial relationship ICH-GCP E6(R2); EU Clinical Trials Regulation 536/2014 Sponsor and investigator/site institution Protocol conduct, funding, indemnity, publication rights

    DTA vs CTA: a narrow instrument inside a broader contract

    A clinical trial agreement is the master contract between sponsor and site: it fixes protocol adherence, payment schedules, indemnification and publication rights for the entire study. Some CTAs include a data-ownership clause stating who holds the master dataset — but that clause states an outcome, not a transfer mechanism. It does not specify the cross-border legal basis, security controls, or destruction deadline that apply once data actually moves to a third party.

    This gap is exactly where a DTA sits. When a sponsor later licenses anonymised trial data to a third-party analytics firm, or a site shares a dataset with an unaffiliated academic collaborator, the CTA’s ownership clause tells you who owns the data — it does not tell you the terms on which someone else may now receive it. A separate DTA closes that gap, keeping the CTA focused on trial conduct and the DTA focused on data movement — a single-purpose separation that research-contracting offices coordinated through ARMA, EARMA and INORMS increasingly recommend.

    What clauses must a clinical trial DTA cover?

    A compliant clinical trial DTA is built around a defined clause set. Where cross-border transfer is involved, the legal transfer mechanism clause is not optional under UK GDPR/EU GDPR Chapter V (Articles 44–49), which requires an adequacy decision, Standard Contractual Clauses, or an equivalent safeguard before personal data leaves the UK or EEA.

    • Purpose limitation — the exact research use(s) the recipient may apply to the data, with no implied right to broader secondary use.
    • Legal transfer mechanism — for cross-border transfers, the EU Standard Contractual Clauses (Implementing Decision (EU) 2021/914, June 2021) or the UK ICO’s International Data Transfer Agreement (IDTA), in force since 21 March 2022 and mandatory for new UK transfer contracts from 21 September 2022.
    • Confidentiality and re-identification prohibition — an express bar on attempting to re-identify anonymised or pseudonymised participants.
    • Security safeguards — encryption in transit and at rest, access controls, and breach-notification timelines.
    • Retention and destruction/return — a fixed deadline by which the recipient must destroy or return the dataset, with certification of destruction.
    • Audit and inspection rights — the data holder’s right to verify the recipient’s compliance.
    • Publication and attribution terms — how the recipient may cite or publish findings derived from the data, and what data-sharing statement language applies.

    Two further reference points shape this clause set. Under the HIPAA Privacy Rule (45 CFR §164.514(e)), a US covered entity sharing a “limited data set” must do so under a Data Use Agreement with materially the same content requirements as a clinical trial DTA. Since July 2018, the ICMJE has required a data-sharing statement as a condition of publication for trials reporting individual patient-level data — so the DTA’s publication and attribution clause is a downstream publication requirement, not a courtesy.

    Frequently asked questions

    What is a data transfer agreement in clinical trials?

    A data transfer agreement (DTA) is a legally binding contract that sets the terms for moving clinical trial data from a data controller to a third-party recipient. It defines permitted use, retention limits, security safeguards and cross-border transfer mechanisms, and applies whenever data — not physical specimens — moves outside the originating study team.

    What is the difference between a DPA and a DSA?

    A Data Processing Agreement (DPA) binds a processor acting strictly on a controller’s instructions, as required by UK GDPR Article 28. A Data Sharing Agreement (DSA) — the closer relative of a clinical trial DTA — governs transfers between two independent controllers who each decide their own purposes for the data.

    What is a material transfer agreement in clinical trials?

    A material transfer agreement (MTA) governs the transfer of tangible items — blood, tissue, biopsies or investigational compounds — between institutions, covering permitted use, ownership of derivatives and liability. Unlike a DTA, an MTA never addresses data itself; a single trial commonly needs both when biological samples travel with associated datasets.

    What is the purpose of a data transfer agreement?

    The purpose of a data transfer agreement is to make a specific transfer of clinical trial data lawful and auditable. It fixes the legal transfer mechanism, restricts secondary use, sets retention and deletion deadlines, and assigns liability if the recipient breaches confidentiality or re-identifies anonymised participants.

    What this means for sponsors, sites and data recipients

    Treating the DTA as a genuine standalone instrument — not a subset of the CTA, and not interchangeable with an MTA — closes a compliance gap that institutional research-contracting offices flag repeatedly. As secondary use of trial data grows through repositories, federated analytics and cross-sponsor licensing, data movements that fall outside the original CTA’s scope will keep rising.

    Research administrators, data protection officers and sponsors gain most by maintaining a standing DTA template — pre-cleared for common transfer scenarios and distinct from their MTA and CTA templates — so a new data recipient can be onboarded against a known, auditable clause set rather than a bespoke renegotiation each time.

    For definitions of related contracting and data-governance terms, research administrators can consult the CASRAI dictionary of research-administration terms; broader context on how these agreements sit within institutional research operations is covered in CASRAI’s research administration content.

  • When Is a Material Transfer Agreement Required? A Decision Framework

    A material transfer agreement is required whenever tangible, non-public research materials — cell lines, plasmids, antibodies, reagents, transgenic organisms, or associated data — move between two separate legal entities and the provider wants to retain ownership, control future use, or protect intellectual property. If the material is freely purchasable on the open market, or if it never leaves the same legal entity, no material transfer agreement is needed. Between those two extremes sits a middle case — a simple loan or implementing letter — that many institutions handle incorrectly, which is the gap this framework closes.

    A material transfer agreement (MTA) is a legally binding contract that sets out the terms under which tangible research materials are supplied by one organisation (the provider) and used by another (the recipient), covering ownership, permitted use, publication rights, liability, and the treatment of any resulting inventions.

    Contents

    What is a material transfer agreement?

    A material transfer agreement is the contract vehicle research institutions use to move physical research materials — rather than data or funding — between organisations while preserving each party’s rights. It typically fixes four things: who owns the original material, what the recipient may do with it, who owns anything invented using it, and whether results can be published without restriction.

    MTAs sit alongside, but are distinct from, confidentiality agreements and sponsored-research agreements. A confidentiality agreement protects information; an MTA protects a physical or biological thing. Where data accompanies the material — sequencing reads, patient metadata, assay results — many institutions issue a linked Data Transfer Agreement (DTA) rather than folding data terms into the MTA itself.

    When is a material transfer agreement required?

    An MTA is required whenever three conditions are all true: the item is tangible (not purely information), it is not freely available for anyone to buy, and the provider wants to attach conditions to its use. Absent any one of those three, a lighter mechanism — or nothing — usually suffices.

    The general triggers

    Institutions typically require a full MTA for: proprietary cell lines and plasmids; genetically modified organisms; patient- or human-derived samples; antibodies or reagents developed in-house; software tied to physical hardware; and any material being sent to, or received from, a for-profit company. The University of Manchester’s contracts team states plainly that an MTA is required for the transfer of materials and/or data between the University and a third party, but explicitly carves out one exception: if the materials are available to purchase on the open market, an MTA will not be required, because that transaction is simply a purchase handled through procurement.

    Special categories that raise the bar

    Three categories demand extra scrutiny before any material moves, regardless of how “routine” the transfer feels:

    • Human-derived material — samples covered by the UK Human Tissue Act 2004 require Human Tissue Authority (HTA) licensing checks and research ethics approval before any transfer agreement is signed.
    • Genetic resources sourced internationally — transfers of genetic material obtained from a provider country after the Nagoya Protocol entered into force in 2014 trigger access-and-benefit-sharing (ABS) obligations under the Convention on Biological Diversity, independent of whatever the MTA itself says.
    • Plant genetic resources for food and agriculture — material listed under the Multilateral System of the International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA, in force since 2004) must move under the FAO’s Standard Material Transfer Agreement (SMTA), a fixed-form contract that cannot be substituted with an institution’s own template.

    Materials crossing borders may also need export-control clearance where dual-use or sensitive technology is involved, and third-party funding terms must be checked for conflicts before an MTA is countersigned — a funder’s data-sharing mandate can directly contradict a provider’s proposed use restrictions.

    The decision framework: full MTA, simple letter, or no agreement

    Most guidance treats “do I need an MTA” as binary. In practice, research offices work with three tiers, and choosing the wrong one either creates unnecessary friction or leaves an institution legally exposed.

    Scenario Mechanism Why
    Unmodified biological material moving between two non-profit institutions that are both signatories to a master agreement Simple implementing/loan letter Terms are pre-agreed once; each transfer just references the master deal, e.g. under the NIH-developed Uniform Biological Material Transfer Agreement (UBMTA)
    Proprietary, modified, human-derived, or export-controlled material; any transfer involving a for-profit party Full negotiated MTA Ownership, publication rights, IP on improvements, and liability all need bespoke terms
    Material freely available for purchase on the open market, or moving within the same legal entity No agreement (procurement or internal process only) There is no proprietary right or cross-entity risk to allocate
    Plant genetic resources under the ITPGRFA Multilateral System FAO Standard Material Transfer Agreement (SMTA) A treaty-mandated fixed form; institutions cannot substitute their own template

    The middle tier is the one most frequently mishandled. Under the UBMTA — a master agreement developed under the auspices of the US National Institutes of Health in 1995 — signatory institutions exchange unmodified biological materials using a one-page implementing letter instead of renegotiating terms each time. But even under UBMTA cover, a full bespoke MTA is still required the moment the material is human-derived, genetically modified, or hazardous, or if either party is not a signatory.

    Practically, ask four questions in order:

    1. Is the material purchasable off the shelf? If yes, stop — use procurement, not an MTA.
    2. Does a signed master agreement (e.g. UBMTA) already cover both institutions and this exact material type unmodified? If yes, a loan/implementing letter is sufficient.
    3. Is either party for-profit, or is the material modified, human-derived, genetically modified, or export-controlled? If yes, a full negotiated MTA is required.
    4. Is the material a plant genetic resource under the ITPGRFA Multilateral System? If yes, the FAO SMTA applies and overrides institutional templates.

    Answer-first Q&A

    Do I need an MTA?

    You need an MTA if you are sending or receiving tangible, non-public research material — biological samples, reagents, cell lines, or similar — to or from a different legal entity. If the material is commercially purchasable or stays within your own institution, no agreement is required; check with your contracts office before assuming either way.

    What is a material transfer agreement?

    A material transfer agreement is a contract between a provider and a recipient organisation that documents the material being transferred and the terms governing its ownership, permitted use, publication, and any resulting inventions. It protects both parties’ intellectual property and clarifies liability before materials change hands.

    What is the standard material transfer agreement (SMTA)?

    The Standard Material Transfer Agreement is the fixed-form contract required under the FAO’s International Treaty on Plant Genetic Resources for Food and Agriculture. It governs transfers of listed plant genetic resources within the treaty’s Multilateral System and cannot be replaced by an institution’s own MTA template.

    Why do institutions require an MTA?

    Institutions require an MTA to protect ownership of proprietary materials, define permitted research use, and settle publication and inventorship rights in advance. Without one, disputes over who owns follow-on discoveries or who may publish first become far harder to resolve after the fact.

    Implications for research administrators

    Getting the tier wrong has real cost on both sides. Forcing every transfer through a full negotiated MTA slows down routine science and burdens contracts teams already stretched thin. Skipping an agreement where one is legally required — particularly for human-derived or export-controlled material — exposes the institution to compliance action and jeopardises the researcher’s ability to publish or patent.

    A working checklist for any incoming or outgoing transfer should confirm: the material’s category (unmodified biological, modified, human-derived, genetic resource, software, data); whether either party is for-profit; whether a signatory master agreement already applies; whether human tissue, Nagoya Protocol, or export-control obligations attach; and who at the institution holds authority to sign, since most universities restrict MTA signature to a small number of authorised contracts officers rather than the individual researcher.

    As research materials increasingly cross borders and sectors — biobanks, industry-academic partnerships, international consortia — the three-tier framework above gives administrators a faster, defensible route to the right mechanism, rather than defaulting every transfer to the slowest, most conservative option. For related definitions and terminology used across research administration, see the CASRAI Dictionary and the broader research administration resource hub.